Mindera Health™ Welcomes New Vice President of Sales

« Back

– Mindera Health, a pioneer in precision medicine combining machine learning with Next-Generation Sequencing to create Dermal Intelligence™, announces the addition of John Wegener as the New VP of Sales.

John has deep experience and impressive accomplishments across his career, including most recently 10 years as Senior Vice President Sales and Marketing at Exagen Inc. and 14 years at Prometheus Laboratories as National Director of Managed Markets. At both organizations John was able to take start-up organizations and turn them into commercial sales leaders.

“We are thrilled to welcome John to the Mindera team,” said Ron Rocca, President and CEO. “I have worked closely with John in the past and find that his extensive experience in diagnostic sales and deep understanding of managed markets will be extremely valuable as we continue to innovate and expand. John shares our commitment to excellence, and we are confident that he will help us achieve new heights in patient, physician, and payor satisfaction as well as revenue growth.”

John expressed excitement about the new role: “I am honored to join Mindera Health at such an exciting time in its growth journey. I look forward to working alongside the talented team here to drive meaningful results and provide all our customers with the highest level of service.” As Vice President of Sales, John will oversee all aspects of Mindera Health’s sales operations, including strategic planning, team development, and customer acquisition. His appointment is part of Mindera Health’s continued commitment to strengthening its leadership team and driving sustainable growth.

About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification.

About Mind.Px™
Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91 percent positive predictive value[i]. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annually. [ii]

i. Bagel J, Wang Y, Montgomery P 111, et al. A machine learning-based test for predicting response to psoriasis biologics. SKIN The Journal of Cutaneous Medicine. 2021;5(6):621-638. doi:10.25251/skin.5.6.5

ii. Wu J, Montgomery P, Long B, et al. An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis. SKIN The Journal of Cutaneous Medicine. 2021;5(4):372-387. doi:10.25251/skin.5.4.6

Ron Rocca

Mr. Rocca brings over two decades of biotech and diagnostics industry experience, including eleven years of developing and commercializing diagnostic products for autoimmune-related diseases. His prior role was President and CEO of Exagen Inc. (NASDAQ: XGN) which commercialized a suite of testing products enabling healthcare providers to improve care for patients through the differential diagnosis, prognosis and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Prior to Exagen, Mr. Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus Laboratories, Inc., a specialty pharmaceutical and diagnostic company focused on diseases in gastroenterology and oncology. He helped grow the company’s sales to $200 million-plus annually before playing an instrumental role in the $1.4 billion acquisition by Nestlé Health Science S.A. in 2011. Prior to Prometheus, Mr. Rocca was the General Manager of Alpharma Inc., a specialty pharmaceutical company. Earlier in his career, Mr. Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a neuroscience-focused biotechnology company. Mr. Rocca received a B.A. in Marketing and Personnel Management from Towson University.

Tobin Dickerson, PhD

Tobin Dickerson joined MiNDERA from the The Scripps Research Institute where he was an Associate Professor in the Department of Chemistry and the Worm Institute for Research and Medicine from 2005-2019. He completed his BS with high honors in Chemistry from the University of Virginia in 1999, and subsequently was awarded his MA in Chemistry in 2000. At that time, he matriculated to TSRI where he completed his PhD in 2004 in Chemical Biology. Toby was promoted to the TSRI faculty in 2005 where he has established a research program aimed at developing disruptive platform technologies for problems of emergent clinical significance. In addition to the MiNDERA technology platform, his laboratory has developed technologies that allow for the prediction of protein evolution, a universal screening system for protein-ligand interactions, and a metabolomics platform for the diagnosis of infectious disease in resource-limited areas.

Toby has >85 publications, and has served as PI of both governmentally and corporately sponsored research from small biotech companies as well as major pharmaceutical firms. His scientific expertise includes diagnostic platform development, small molecule and vaccine discovery, metabolomics, scientific algorithm and software development, phage display, and neglected tropical diseases.

Mindera Health™ Welcomes New Vice President of Sales

Ron Rocca

Tobin Dickerson, PhD

Contact

Hours

Mindera Health